Biocad, Millhouse, Pharmstandard deal

Pharmstandard and Russian investment firm Millhouse completed the acquisition of a combined 70% stake in Russian biosimilar play Biocad. Pharmstandard acquired a 20% stake and Millhouse acquired a 50%...